Phillip Burk
Foot & Ankle Surgery · Caldwell, IDNPI 1306064258
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $10,969 of the $13,387 with a category attached, or 81.9%. Smart-surgical Inc. Dba Burst Biologics accounts for 79.7% of it on its own, with 10 other manufacturers making up the rest. Reporting peaked in 2020 at $6,476 and has fallen 97.1% since, to $191 in 2025.
Across 39 payments — averaging $343.25 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Smart-surgical Inc. Dba Burst Biologics$11K
- Steelhead Surgical Inc$1K
- Arthrex$592
- Galt Pharmaceuticals, LLC$300
- Stryker$250
- Integra Lifesciences Corporation$127
- plus $176 from 5 others
What the payments were for
- Consulting fees$10,96982%
- Travel & lodging$1,0268%
- Food & beverage$9277%
- Education$4653%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Smart-surgical Inc. Dba Burst Biologics | 2 | $10,669 |
| Steelhead Surgical Inc | 7 | $1,274 |
| Arthrex | 11 | $592 |
| Galt Pharmaceuticals, LLC | 1 | $300 |
| Stryker | 8 | $250 |
| Integra Lifesciences Corporation | 2 | $127 |
| Curonix LLC | 4 | $59 |
| Fusion Orthopedics USA, LLC | 1 | $48 |
| Averitas Pharma Inc. | 1 | $30 |
| Organogenesis Inc. | 1 | $28 |
| Amgen | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- BioBurst Fluid$10,669
- Orphengesic Forte$300
How this compares
$13,387 in reported general payments places this provider in the 80th percentile of 49 foot & ankle surgery providers in Idaho.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Naftifine Hcl | 20 | $8,462 |
| Halobetasol Propionate | 18 | $2,077 |
| Ketoconazole | 35 | $893 |
| Celecoxib | 14 | $886 |
| Diclofenac Sodium ErDiclofenac Sodium | 15 | $725 |
| Gabapentin | 24 | $548 |
| Terbinafine Hcl | 17 | $292 |
| Cephalexin | 11 | $95 |
Paid to pharmacies, not to this prescriber.
Other foot & ankle surgery in Caldwell
- Jed EricksonCaldwell$800
- Kaitlin NearyBoise$867K
- Dan RobinsonBlackfoot$170K
- Kurt KinghornMeridian$150K
- Steven RoserBoise$102K
- Bryan VandykeIdaho Falls$47K
- Jonathon WolfMeridian$22K
- Christopher ArenaCoeur D Alene$14K
- Karson HowardPocatello$14K
- Jason DevriesTwin Falls$12K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.